Boardroom Media (CFO News)
At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Switzerland based CFO’ operating in the Biotechnology space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Erwin Troxler
CFO of HBM Partners
Erwin Toxler, CPA is the Chief Financial Officer of HBM Partners Ltd. He has been employed at the firm Since 2005. He has headed up several areas within the Finance Department at HBM Partners since 2005. He has over 10 years of experience in audit management and private equity. Before joining HBM Partners, he gained several years of experience in the private equity business with Julius Baer. He spent a number of years at Julius Baer Group Ltd., looking after investment companies in the private equity segment. Prior to this, he served as an Audit Manager of PricewaterhouseCoopers LLP in Switzerland, with clients in the financial services industry between 1999 – 2002. He was also a Credit Administrator at Luzerner Kantonalbank between 1990 – 1993. He was responsible for management of several areas within the Finance Departments between 2005-2011. Between 2002 – 2005 he served as a Vice President of Julius Bar Family Office, responsible for investment companies in the private equity segment. He is a Member of the Board of Directors at HBM Public Equity Advisors Ltd Since 2012 and HBM Business Advisory Ltd Since 2007. He is a Swiss Certified Public Accountant. Mr. Toxler holds a degree of the Lucerne School of Economics and Business Administration.
Follow Erwin Troxler:
About HBM Healthcare Investments AG, HBM Partners: HBM Partners was founded in 2001 with the goal to invest in private and public emerging biopharma and other healthcare-related companies.
Fernando Cunha
CFO of AB2 Bio
Follow Fernando Cunha:
About AB2 Bio: AB2 Bio is a drug discovery and development company.
Valentin Matillon
SVP – Chief Financial Officer of SOPHiA GENETICS
Valentin Matillon joined SOPHiA GENETICS in 2018 as Chief Financial Officer. He is a seasoned finance executive with over 20 years of leadership experience in IT, Telecommunications and MedTech companies. He has held a number of senior finance management positions at SITA, Electronic Arts and Hewlett-Packard, including Group CFO, senior finance director in charge of corporate finance, financial planning & analysis, and performance management programs. Most recently, as senior finance director at the Hobart Group, Valentin led the corporate finance, financing & accounting operations team. As CFO, Valentin focuses on increasing shareholder value by driving global financial excellence and long-term sustainability. In addition to leading the Finance organization, Valentin is also in charge of the Legal department and Business Development activities. He received his Finance B.A. from Institut des Hautes Etudes Economiques et Commerciales de Paris and his MS from Ecole Centrale de Paris, France. “It is not the strongest of the species that survives, but the most adaptable” – Charles Darwin
Follow Valentin Matillon:
About NOVIGENIX, SOPHiA GENETICS: SOPHiA GENETICS is a biotechnology firm that aims to support healthcare professionals by maximizing the power of data-driven medicine.
Andrew Oakley
CFO of NovImmune
Andrew J. Oakley joined Novimmune as Chief Financial Officer in March 2014, bringing with him over 30 years of professional experience in pharmaceutical, financial, and industrial organizations. Previously, Andrew served for ten years as Executive Vice President and Chief Financial Officer at Actelion Ltd., a global biopharmaceutical leader headquartered in Switzerland. During his tenure there, Andrew led the financial functions of the company as it grew from 200 employees with sales of CHF 100 million into a global enterprise with 2,500 employees and sales of CHF 1.7 billion. The company’s market capitalization also multiplied from CHF 1.5 billion to CHF 7.5 billion during that time. Prior to Actelion, Andrew was a senior finance executive with Accenture, the global business consultancy, and held a number of additional senior management and finance roles at financial and industrial organisations in Australia, the UK and the US. An Australian citizen, Andrew Oakley holds a Bachelor of Economics from Macquarie University in Sydney and an MBA from the London Business School. He also holds an ACA qualification from the Australian Institute of Chartered Accounting.
Follow Andrew Oakley:
About Autolus, NovImmune: NovImmmune develops therapeutic monoclonal antibodies to treat patients suffering from immune-related disorders.
Andrew Smith
Chief Financial Officer of Allecra Therapeutics
Andrew has over 30 years’ experience in finance within the pharma and medical device industry as well as in public accounting. He served as Vice President Finance and Chief Financial Officer of Sucampo Pharmaceuticals Inc between 2011 – 2017 and has held other management positions with a number of other companies within Europe, Asia and USA. He is a Fellow of the Institute of Management Accountants and a Chartered Global Management Accountant and has studied business and accounting at Liverpool John Moore’s University and Durham University Business School.
Follow Andrew Smith:
About Allecra Therapeutics: Allecra is a biopharmaceutical company focused on the development of novel treatments to combat multi-drug-resistant bacterial infections.
Andrew Moore
Chief Financial Officer of Humedics
Andrew Moore, a Swiss and British national, has been a member of the executive management team of medium-sized and small companies in the healthcare sector for almost 20 years. Previously, he worked in sales and finance in banking for more than 20 years in both London and Zurich. Most recently, he was CFO at LifeWatch AG, a Swiss listed cardiac monitoring company which was acquired by a US competitor. Previously, he was CEO/CFO at several start-ups and Chief Investment Officer for two listed investment companies focusing on sustainable start-ups. Andrew´s experience includes raising finance, publishing a prospectus, overseeing several due diligence processes and successful selling companies. He has a BSc. in Statistics and Operational Research from the University of Leeds and is a qualified English Chartered Accountant (FCA), qualified English Tax Advisor (CTA), certified European Financial Analyst (CEFA) and holds a Certificate in Corporate Governance from INSEAD.
Follow Andrew Moore:
About Humedics: Humedics specializes in instant and exact liver function measurement.
Andrew Moore
Chief Financial Officer of Humedics
Andrew Moore, a Swiss and British national, has been a member of the executive management team of medium-sized and small companies in the healthcare sector for almost 20 years. Previously, he worked in sales and finance in banking for more than 20 years in both London and Zurich. Most recently, he was CFO at LifeWatch AG, a Swiss listed cardiac monitoring company which was acquired by a US competitor. Previously, he was CEO/CFO at several start-ups and Chief Investment Officer for two listed investment companies focusing on sustainable start-ups. Andrew´s experience includes raising finance, publishing a prospectus, overseeing several due diligence processes and successful selling companies. He has a BSc. in Statistics and Operational Research from the University of Leeds and is a qualified English Chartered Accountant (FCA), qualified English Tax Advisor (CTA), certified European Financial Analyst (CEFA) and holds a Certificate in Corporate Governance from INSEAD.
Follow Andrew Moore:
About Humedics: Humedics specializes in instant and exact liver function measurement.
Urs Breitenstein
CFO of Strekin
URS BREITENSTEIN CHIEF FINANCE OFFICER Dr. Urs Breitenstein supports companies and investors with his corporate transactions, financing or valuation expertise and with his network. As a partner of Hoffmann & Co AG, a Swiss M&A and CFO services company, he is involved with several startups and growth companies in the life science sector as interim or part time CFO, as business advisor or as a board As a board member, he also represents an investment company. Urs previously served for more than ten years as a team leader and partner at international professional service firms (PwC, Deloitte) providing valuation, corporate finance and M&A services. He supported many large and mid-sized life science (but also manufacturing and service sector) transactions in Switzerland and in Europe. He is a graduate of the postgraduate study centre of the Swiss National Bank at Gerzensee and holds a doctorate in economics from the University of Basel.
Follow Urs Breitenstein:
About Hoffmann & partner, Kinarus AG, Strekin, Versameb: Strekin AG is a clinical-stage biopharmaceutical company headquartered in Basel, Switzerland.
André C Muller
EVP, Chief Financial Officer of Idorsia
Follow André C Muller:
About Idorsia: The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients.
Robin Berger
Chief Financial Officer of KetoSwiss
Robin Berger is the Chief Financial Officer at KetoSwiss.
Follow Robin Berger:
About KetoSwiss: KetoSwiss is a Swiss-based BioTech startup that strives to bring ketone bodies back into the modern world to combat diseases.
Robin Berger
Chief Financial Officer of KetoSwiss
Robin Berger is the Chief Financial Officer at KetoSwiss.
Follow Robin Berger:
About KetoSwiss: KetoSwiss is a Swiss-based BioTech startup that strives to bring ketone bodies back into the modern world to combat diseases.
Gert Schaumburg
Vice President, Finance & CFO of Leica Biosystems
Vice President, Finance & CFO at Leica Biosystems .
Follow Gert Schaumburg:
About Leica Biosystems, Leica Biosystems St. Louis: Leica Biosystems develops laboratory workflow solutions for anatomic pathology involved in the advancement of cancer diagnostics.
Christophe Guichard
Chief Businesss Officer, CFO and Board Member of NETRIS Pharma
Follow Christophe Guichard:
About ArisGen, Eclosion SA, NETRIS Pharma: NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the pharmaceutical industry.
Khaled Bahi
CFO of Stilla Technologies
Follow Khaled Bahi:
About Stilla Technologies: Stilla Technologies is a Paris-based european biotechnology company.
Rudolf Eugster
Chief Financial Officer of Tecan
Follow Rudolf Eugster:
About Tecan: Tecan is a global provider of automated laboratory instruments and solutions.
Marco Pizzichini
CFO of Novaton
Follow Marco Pizzichini:
About Novaton: Novaton develops and sells clean tech systems for the aquaculture industry.
Reto Suter
CFO of Siegfried Holding
Reto Suter serves as the Chief Financial Officer of the Siegfried Group.
Follow Reto Suter:
About Siegfried Holding: Siegfried Holding is a pharmaceutical company that offers and manufactures primary and secondary drug substances and products.
ANDREAS BORNER
CFO of Dectris
Follow ANDREAS BORNER:
About Dectris: Dectris is one of the technical leading companies in X-ray detection.
ANDREAS BORNER
CFO of Dectris
Follow ANDREAS BORNER:
About Dectris: Dectris is one of the technical leading companies in X-ray detection.
